Skip to main content
Erschienen in: Intensive Care Medicine 11/2014

01.11.2014 | Original

PROF-ETEV study: prophylaxis of venous thromboembolic disease in critical care units in Spain

verfasst von: Pablo García-Olivares, Jose Eugenio Guerrero, Pedro Galdos, Demetrio Carriedo, Francisco Murillo, Antonio Rivera

Erschienen in: Intensive Care Medicine | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Venous thromboembolic disease (VTE) in critically ill patients has a high incidence despite prophylactic measures. This fact could be related to an inappropriate use of these measures due to the absence of specific VTE risk scores. To assess the current situation in Spain, we have performed a cross-sectional study, analyzing if the prophylactic measures were appropriate to the patients’ VTE risk.

Methods

Through an electronic questionnaire, we carried out a single day point prevalence study on the VTE prophylactic measures used in several critical care units in Spain. We performed a risk stratification for VTE in three groups: low, moderate–high, and very high risk. The American College of Chest Physicians guidelines were used to determine if the patients were receiving the recommended prophylaxis.

Results

A total of 777 patients were included; 62 % medical, 30 % surgical, and 7 % major trauma patients. The median number of the risk factors for VTE was four. According to the proposed VTE risk score, only 2 % of the patients were at low risk, whereas 83 % were at very high risk. Sixty-three percent of patients received pharmacological prophylaxis, 12 % mechanical prophylaxis, 6 % combined prophylaxis, and 19 % did not receive any prophylactic measure. According to criteria suggested by the guidelines, 23 % of medical, 71 % of surgical, and 70 % of major trauma patients received an inappropriate prophylaxis.

Conclusions

Most critically ill patients are at high or very high risk of VTE, but there is a low rate of appropriate prophylaxis. The efforts to improve the identification of patients at risk, and the implementation of appropriate prevention protocols should be enhanced.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Geer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M, VTE Impact Assessment Group in Europe (VITAE) (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98:756–764PubMed Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Geer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M, VTE Impact Assessment Group in Europe (VITAE) (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98:756–764PubMed
2.
Zurück zum Zitat Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268–1279PubMedCrossRef Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268–1279PubMedCrossRef
3.
Zurück zum Zitat PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook DD, Meade M, Guyatt G, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–1314. doi:10.1056/NEJMoa1014475 PubMedCrossRef PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook DD, Meade M, Guyatt G, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–1314. doi:10.​1056/​NEJMoa1014475 PubMedCrossRef
4.
Zurück zum Zitat Khouli H, Shapiro J, Pham VP, Arfaei A, Esan O, Jean R, Homel P (2006) Efficacy of deep venous thrombosis prophylaxis in the medical intensive care unit. J Intensive Care Med 21:352–358PubMedCrossRef Khouli H, Shapiro J, Pham VP, Arfaei A, Esan O, Jean R, Homel P (2006) Efficacy of deep venous thrombosis prophylaxis in the medical intensive care unit. J Intensive Care Med 21:352–358PubMedCrossRef
5.
Zurück zum Zitat Clagett GP, Anderson FA Jr, Levine MN, Salzman EW, Wheeler HB (1992) Prevention of venous thromboembolism. Chest 102:391S–407SPubMedCrossRef Clagett GP, Anderson FA Jr, Levine MN, Salzman EW, Wheeler HB (1992) Prevention of venous thromboembolism. Chest 102:391S–407SPubMedCrossRef
6.
Zurück zum Zitat Geerts WH, Pineo GF, Bergqvist D, Lassen, Colwen CW, Ray J (2004) Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:338S–400SPubMedCrossRef Geerts WH, Pineo GF, Bergqvist D, Lassen, Colwen CW, Ray J (2004) Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:338S–400SPubMedCrossRef
7.
Zurück zum Zitat Sud S, Mittmann N, Cook DJ, Geerts W, Chan B, Dodek P, Gould MK, Guyatt G, Arabi Y, Fowler RA (2011) Screening and prevention of venous thromboembolism in critically ill patients a decision analysis and economic evaluation. Am J Respir Crit Care Med 184:1289–1298. doi:10.1164/rccm.201106-1059OC PubMedCrossRef Sud S, Mittmann N, Cook DJ, Geerts W, Chan B, Dodek P, Gould MK, Guyatt G, Arabi Y, Fowler RA (2011) Screening and prevention of venous thromboembolism in critically ill patients a decision analysis and economic evaluation. Am J Respir Crit Care Med 184:1289–1298. doi:10.​1164/​rccm.​201106-1059OC PubMedCrossRef
9.
Zurück zum Zitat Lacherade JC, Cook D, Heyland D, Chrusch C, Brochard L, Brun-Buisson Ch; French and Canadian ICU Directors Groups (2003) Prevention of venous thromboembolism in critically ill medical patients: a Franco-Canadian cross-sectional study. J Crit Care 18:228–237CrossRef Lacherade JC, Cook D, Heyland D, Chrusch C, Brochard L, Brun-Buisson Ch; French and Canadian ICU Directors Groups (2003) Prevention of venous thromboembolism in critically ill medical patients: a Franco-Canadian cross-sectional study. J Crit Care 18:228–237CrossRef
10.
Zurück zum Zitat Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA Jr, IMPROVE investigators (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on venous thromboembolism. Chest 132:936–945PubMedCrossRef Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA Jr, IMPROVE investigators (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on venous thromboembolism. Chest 132:936–945PubMedCrossRef
11.
Zurück zum Zitat Robertson MS, Nichol AD, Higgins AM, Bailey MJ, Presneill JJ, Cooper DJ, Webb SA, McArthur C, Maclsaac CM, VTE Point Prevalence Investigators for the Australian and New Zealand Intensive Care Research Centre, Australian and New Zealand Intensive Care Society Clinical Trials Group (2010) Venous thromboembolism prophylaxis in the critically ill: a point prevalence survey of current practice in Australian and New Zealand intensive care units. Crit Care Resusc 12:9–15PubMed Robertson MS, Nichol AD, Higgins AM, Bailey MJ, Presneill JJ, Cooper DJ, Webb SA, McArthur C, Maclsaac CM, VTE Point Prevalence Investigators for the Australian and New Zealand Intensive Care Research Centre, Australian and New Zealand Intensive Care Society Clinical Trials Group (2010) Venous thromboembolism prophylaxis in the critically ill: a point prevalence survey of current practice in Australian and New Zealand intensive care units. Crit Care Resusc 12:9–15PubMed
12.
Zurück zum Zitat Schaden E, Metnitz PG, Pfanner G, Heil S, Pernerstorfer T, Perger P, Schoechl H, Fries D, Guetl M, Kozek-Langenecker S (2012) Coagulation day 2010: an Austrian survey on the routine of thromboprophylaxis in intensive care. Intensive Care Med 38:984–990. doi:10.1007/s00134-012-2533-0 PubMedCrossRef Schaden E, Metnitz PG, Pfanner G, Heil S, Pernerstorfer T, Perger P, Schoechl H, Fries D, Guetl M, Kozek-Langenecker S (2012) Coagulation day 2010: an Austrian survey on the routine of thromboprophylaxis in intensive care. Intensive Care Med 38:984–990. doi:10.​1007/​s00134-012-2533-0 PubMedCrossRef
13.
Zurück zum Zitat Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Belekian AA, Klein RC, Le H, Schulman S, Murad MH, American College of Chest Physicians (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e195S–226S. doi:10.1378/chest.11-2296 PubMedPubMedCentral Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Belekian AA, Klein RC, Le H, Schulman S, Murad MH, American College of Chest Physicians (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e195S–226S. doi:10.​1378/​chest.​11-2296 PubMedPubMedCentral
14.
Zurück zum Zitat Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM, American College of Chest Physicians (2012) Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e227S–277S. doi:10.1378/chest.11-2297 PubMedPubMedCentral Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM, American College of Chest Physicians (2012) Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e227S–277S. doi:10.​1378/​chest.​11-2297 PubMedPubMedCentral
17.
Zurück zum Zitat Rocha AT, Paiva EF, Lichtenstein A, Milani R Jr, Cavalheiro-Filho C, Maffei FH (2007) Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vasc Health Risk Manag 3:533–553PubMed Rocha AT, Paiva EF, Lichtenstein A, Milani R Jr, Cavalheiro-Filho C, Maffei FH (2007) Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vasc Health Risk Manag 3:533–553PubMed
18.
Zurück zum Zitat Mesgarpour B, Heidinger BH, Schwameis M, Kienbacher C, Walsh C, Schmitz S, Herkner H (2013) Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis. Intensive Care Med 39:1896–1908. doi:10.1007/s00134-013-3030-9.Epub PubMedCrossRef Mesgarpour B, Heidinger BH, Schwameis M, Kienbacher C, Walsh C, Schmitz S, Herkner H (2013) Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis. Intensive Care Med 39:1896–1908. doi:10.​1007/​s00134-013-3030-9.​Epub PubMedCrossRef
19.
Zurück zum Zitat Caprini JA, Arcelus JI, Reyna JJ (2001) Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 38:12S–19SCrossRef Caprini JA, Arcelus JI, Reyna JJ (2001) Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 38:12S–19SCrossRef
20.
Zurück zum Zitat Caprini JA (2005) Thrombosis risk assessment as a guide to quality patient care. Dis Mon 51:70–78PubMedCrossRef Caprini JA (2005) Thrombosis risk assessment as a guide to quality patient care. Dis Mon 51:70–78PubMedCrossRef
21.
Zurück zum Zitat Decousus H, Tapson VF, Bergman JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F, Spencer FA, Spyropoulos AC, Turpie AG, Zotz RB, Fitzgerald G, Anderson FA (2011) Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139:69–79. doi:10.1378/chest.09-3081 PubMedCrossRef Decousus H, Tapson VF, Bergman JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F, Spencer FA, Spyropoulos AC, Turpie AG, Zotz RB, Fitzgerald G, Anderson FA (2011) Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139:69–79. doi:10.​1378/​chest.​09-3081 PubMedCrossRef
22.
Zurück zum Zitat Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, Cook R, Webert KE, McDonald E, Cook DJ (2007) Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med 30:E93–E102PubMed Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, Cook R, Webert KE, McDonald E, Cook DJ (2007) Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med 30:E93–E102PubMed
23.
Zurück zum Zitat Lauzier F, Arnold DM, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, Ashley BJ, Albert M, Khwaja K, Ostermann M, Skrobik Y, Fowler R, McIntyre L, Nates JL, Karachi T, Lopes RD, Zytaruk N, Finfer S, Crowther M, Cook D (2013) Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med 39:2135–2143. doi:10.1007/s00134-013-3044-3 PubMedCrossRef Lauzier F, Arnold DM, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, Ashley BJ, Albert M, Khwaja K, Ostermann M, Skrobik Y, Fowler R, McIntyre L, Nates JL, Karachi T, Lopes RD, Zytaruk N, Finfer S, Crowther M, Cook D (2013) Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med 39:2135–2143. doi:10.​1007/​s00134-013-3044-3 PubMedCrossRef
24.
Zurück zum Zitat Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G (2005) Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 33:1565–1571PubMedCrossRef Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G (2005) Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 33:1565–1571PubMedCrossRef
25.
Zurück zum Zitat Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ (2013) Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med 41:2088–2098. doi:10.1097/CCM.0b013e31828cf104 PubMedCrossRef Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ (2013) Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med 41:2088–2098. doi:10.​1097/​CCM.​0b013e31828cf104​ PubMedCrossRef
28.
Zurück zum Zitat Cheng SS, Nordenholz K, Matero D, Pearlman N, McCarter M, Gajdos C, Hamiel C, Baer A, Luzier E, Tran ZV, Olson T, Queensland K, Lutz R, Wischmeyer P (2012) Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. Intensive Care Med 38:642–6488. doi:10.1007/s00134-011-2453-4.Epub PubMedCrossRef Cheng SS, Nordenholz K, Matero D, Pearlman N, McCarter M, Gajdos C, Hamiel C, Baer A, Luzier E, Tran ZV, Olson T, Queensland K, Lutz R, Wischmeyer P (2012) Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. Intensive Care Med 38:642–6488. doi:10.​1007/​s00134-011-2453-4.​Epub PubMedCrossRef
29.
Zurück zum Zitat Kanaan AO, Silva MA, Donovan JL, Silva MA, Donovan JL, Roy T, AI-Homsi AS (2007) Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clin Ther 28:2395–2405CrossRef Kanaan AO, Silva MA, Donovan JL, Silva MA, Donovan JL, Roy T, AI-Homsi AS (2007) Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clin Ther 28:2395–2405CrossRef
31.
Zurück zum Zitat Holbrook A, Schulman S, Witt DM, Olav Vandvik P, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH, American College of Chest Physicians (2012) Evidence-based management of anticoagulant therapy antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–184S. doi:10.1378/chest.11-2295 PubMedPubMedCentral Holbrook A, Schulman S, Witt DM, Olav Vandvik P, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH, American College of Chest Physicians (2012) Evidence-based management of anticoagulant therapy antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–184S. doi:10.​1378/​chest.​11-2295 PubMedPubMedCentral
32.
Zurück zum Zitat Dörffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Buoller HR, Levi M (2002) Bioavailability of subcutaneous low molecular-weight heparin to patients on vasopressors. Lancet 359:849–850PubMedCrossRef Dörffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Buoller HR, Levi M (2002) Bioavailability of subcutaneous low molecular-weight heparin to patients on vasopressors. Lancet 359:849–850PubMedCrossRef
33.
Zurück zum Zitat Rommers MK, van der Lely N, Egberts TC, van den Bemt PM (2006) Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care 10:R93PubMedCrossRefPubMedCentral Rommers MK, van der Lely N, Egberts TC, van den Bemt PM (2006) Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care 10:R93PubMedCrossRefPubMedCentral
34.
Zurück zum Zitat Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Baje M, Kong A, Lekawa ME, Dolich MO, Cinat ME, Barrios C, Hoyt DB (2010) Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 68:870–874. doi:10.1097/TA.0b013e3181d32271 CrossRef Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Baje M, Kong A, Lekawa ME, Dolich MO, Cinat ME, Barrios C, Hoyt DB (2010) Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 68:870–874. doi:10.​1097/​TA.​0b013e3181d32271​ CrossRef
35.
Zurück zum Zitat Cook D, Arabi Y, Ferguson N, Heels-Ansdell D, Freitag A, McDonald E, Clarke F, Keenan S, Pagliarello G, Plaxton W, Herridge M, Karachi T, Vallance S, Cade J, Crozier T, da Alves S Silva, Costa Filho R, Brandao N, Watpool I, McArdle T, Hollinger G, Mandourah Y, Al-Hazmi M, Zytaruk N, Adhikari NK, PROTECT Research Coordinators, PROTECT Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group (2013) Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis. Intensive Care Med 39:2115–2125PubMedCrossRef Cook D, Arabi Y, Ferguson N, Heels-Ansdell D, Freitag A, McDonald E, Clarke F, Keenan S, Pagliarello G, Plaxton W, Herridge M, Karachi T, Vallance S, Cade J, Crozier T, da Alves S Silva, Costa Filho R, Brandao N, Watpool I, McArdle T, Hollinger G, Mandourah Y, Al-Hazmi M, Zytaruk N, Adhikari NK, PROTECT Research Coordinators, PROTECT Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group (2013) Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis. Intensive Care Med 39:2115–2125PubMedCrossRef
36.
Zurück zum Zitat Vignon P, Dequin PF, Renault A et al (2013) Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding hospitalized in intensive care units: the CIREA1 randomized trial. Intensive Care Med 39:872–880. doi:10.1007/s00134-013-2814-2 PubMedCrossRef Vignon P, Dequin PF, Renault A et al (2013) Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding hospitalized in intensive care units: the CIREA1 randomized trial. Intensive Care Med 39:872–880. doi:10.​1007/​s00134-013-2814-2 PubMedCrossRef
37.
Zurück zum Zitat Arabi YM, Khedr M, Dara SI, Dhar GS, Bhat SA, Tamim HM, Afesh LY (2013) Use of intermittent pneumatic compression and not graduated compression stockings is associated with lower incident VTE in critically ill patients: a multiple propensity scores adjusted analysis. Chest 144:152–159. doi:10.1378/chest.12-2028 PubMedCrossRef Arabi YM, Khedr M, Dara SI, Dhar GS, Bhat SA, Tamim HM, Afesh LY (2013) Use of intermittent pneumatic compression and not graduated compression stockings is associated with lower incident VTE in critically ill patients: a multiple propensity scores adjusted analysis. Chest 144:152–159. doi:10.​1378/​chest.​12-2028 PubMedCrossRef
38.
Zurück zum Zitat CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M, Sandercock P, Reid J, Graham C, Forbes J, Murray G (2013) Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 382:516–524. doi:10.1016/S0140-6736(13)61050-8 PubMedCrossRef CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M, Sandercock P, Reid J, Graham C, Forbes J, Murray G (2013) Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 382:516–524. doi:10.​1016/​S0140-6736(13)61050-8 PubMedCrossRef
40.
Zurück zum Zitat Kakkos SK, Caprini JA, Geroulakos G et al (2011) Can combined (mechanical and pharmacological) modalities prevent fatal VTE? Int Angiol 30:115–122PubMed Kakkos SK, Caprini JA, Geroulakos G et al (2011) Can combined (mechanical and pharmacological) modalities prevent fatal VTE? Int Angiol 30:115–122PubMed
Metadaten
Titel
PROF-ETEV study: prophylaxis of venous thromboembolic disease in critical care units in Spain
verfasst von
Pablo García-Olivares
Jose Eugenio Guerrero
Pedro Galdos
Demetrio Carriedo
Francisco Murillo
Antonio Rivera
Publikationsdatum
01.11.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 11/2014
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-014-3442-1

Weitere Artikel der Ausgabe 11/2014

Intensive Care Medicine 11/2014 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.